PET-guided treatment and monitoring for limited-stage lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study tests a treatment approach guided by PET scans, plus non-invasive monitoring, for adults with limited-stage diffuse large B-cell lymphoma (a type of lymphoma). It may help by tailoring therapy based on scan and other follow-up information, aiming for better outcomes with fewer invasive steps.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have not had treatment yet for limited-stage non-bulky diffuse large B-cell lymphoma (DLBCL), based on standard staging scans and bone marrow biopsy results
- Your cancer shows up on an FDG-PET scan (a special PET scan that highlights active disease)
- You can provide tumor tissue from a biopsy (archived tissue or a fresh/frozen sample)
- Your blood counts, heart, kidneys, and liver tests meet study limits
- You do not have “bulky” tumors larger than 10 cm in any one direction
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a blood test (ctDNA) and PET scans to predict how well standard first-line treatment works for diffuse large B-cell lymphoma (DLBCL). It aims to find out if these tests can guide better care.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This Phase 2 study tests a treatment sequence for people with high-risk diffuse large B-cell lymphoma (DLBCL) that includes loncastuximab plus rituximab, then DA-EPOCH-R. It aims to improve responses in patients whose lymphoma has specific high-risk features.
This trial compares two different lengths of chemotherapy (4 cycles vs. 6 cycles) combined with two targeted drugs, polatuzumab vedotin and rituximab, for people with newly diagnosed DLBCL who have a low-risk score. The goal is to see if a shorter treatment works just as well with fewer side effects.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This study follows patients with aggressive B-cell lymphoma during treatment using advanced blood tests (ctDNA) and PET imaging to detect how well the cancer is responding. The goal is to find better ways to monitor treatment in real time.
Hear when a new DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.